These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2033396)

  • 21. [A study of trientine therapy in Wilson's disease with neurological symptoms].
    Suda M; Kubota J; Yamaguchi Y; Fujioka Y; Saito Y; Aoki T
    No To Hattatsu; 1993 Sep; 25(5):429-34. PubMed ID: 8398232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissolution of copper-rich granules in hepatic lysosomes by D-penicillamine prevents the development of fulminant hepatitis in Long-Evans cinnamon rats.
    Klein D; Lichtmannegger J; Heinzmann U; Summer KH
    J Hepatol; 2000 Feb; 32(2):193-201. PubMed ID: 10707858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
    Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
    Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Copper level and metallothionein-like Cu-binding protein in cultured skin fibroblasts from patients with Menkes' disease and Wilson's disease].
    Sato M; Hayashi A; Ito H; Tojo M; Arima M
    No To Shinkei; 1984 Nov; 36(11):1063-8. PubMed ID: 6525319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wilson's disease.
    Ala A; Walker AP; Ashkan K; Dooley JS; Schilsky ML
    Lancet; 2007 Feb; 369(9559):397-408. PubMed ID: 17276780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spatial investigation of the elemental distribution in Wilson's disease liver after d-penicillamine treatment by LA-ICP-MS.
    Hachmöller O; Zibert A; Zischka H; Sperling M; Groba SR; Grünewald I; Wardelmann E; Schmidt HH; Karst U
    J Trace Elem Med Biol; 2017 Dec; 44():26-31. PubMed ID: 28965585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wilson's disease: current status.
    Yarze JC; Martin P; Muñoz SJ; Friedman LS
    Am J Med; 1992 Jun; 92(6):643-54. PubMed ID: 1605146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical considerations for an effective medical therapy in Wilson's disease.
    Weiss KH; Stremmel W
    Ann N Y Acad Sci; 2014 May; 1315():81-5. PubMed ID: 24754532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effects of trientine, a copper-chelating agent, on induction of DNA strand breaks in hepatic cells of Long-Evans Cinnamon rats.
    Hayashi M; Miyane K; Hirooka T; Endoh D; Higuchi H; Nagahata H; Nakayama K; Kon Y; Okui T
    Biochim Biophys Acta; 2004 Nov; 1674(3):312-8. PubMed ID: 15541301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wilson's disease in pregnancy.
    Nunns D; Hawthorne B; Goulding P; Maresh M
    Eur J Obstet Gynecol Reprod Biol; 1995 Sep; 62(1):141-3. PubMed ID: 7493698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Wilson's disease: penicillamine or triene?
    Kiechl SG; Willeit J; Aichner F; Felber S
    Acta Neurol Scand; 1992 Feb; 85(2):154-7. PubMed ID: 1574992
    [No Abstract]   [Full Text] [Related]  

  • 32. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease.
    Martins da Costa C; Baldwin D; Portmann B; Lolin Y; Mowat AP; Mieli-Vergani G
    Hepatology; 1992 Apr; 15(4):609-15. PubMed ID: 1551638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease.
    Walshe JM
    QJM; 2011 Sep; 104(9):775-8. PubMed ID: 21622540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A copper-sulfur complex in the liver of a patient with Wilson's disease.
    Sasa A; Hayashi H; Yagi A; Ohguchi S; Kidokoro R; Sato Y; Sakamoto N
    Gastroenterol Jpn; 1986 Dec; 21(6):633-7. PubMed ID: 3569749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wilson's disease: an update, with emphasis on new approaches to treatment.
    Brewer GJ; Yuzbasiyan-Gurkan V
    Dig Dis; 1989; 7(4):178-93. PubMed ID: 2663256
    [No Abstract]   [Full Text] [Related]  

  • 36. Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent.
    Smirnova J; Kabin E; Järving I; Bragina O; Tõugu V; Plitz T; Palumaa P
    Sci Rep; 2018 Jan; 8(1):1463. PubMed ID: 29362485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy.
    Brewer GJ; Johnson VD; Dick RD; Hedera P; Fink JK; Kluin KJ
    Hepatology; 2000 Feb; 31(2):364-70. PubMed ID: 10655259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination treatment with penicillamine and trientine in a patient with Wilson's disease.
    Kobayashi S; Kodama H; Inuzuka R; Mori Y; Yanagawa Y
    Pediatr Int; 2005 Oct; 47(5):589-91. PubMed ID: 16190972
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular localization of copper and zinc in rat fetal liver in dietary and drug-induced copper deficiency.
    Keen CL; Cohen NL; Hurley LS; Lönnerdal B
    Biochem Biophys Res Commun; 1984 Feb; 118(3):697-703. PubMed ID: 6704101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
    Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.